MADRIGAL PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$274.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$274.00K, a 137.95% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $209.00K.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$43.00K, a 102.62% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $722.00K.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $405.00K.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $500.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$274.00K 10-Q · filed 2026-07-30 | -$65.00K 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $209.00K 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $405.00K 10-K · filed 2026-02-19 | |||
| 2025-09-30 | -$43.00K 10-Q · filed 2025-11-04 | $679.00K derived: sum of 2 quarters · filed 2026-07-30 | $600.00K derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $722.00K 10-Q · filed 2026-07-30 | $643.00K 10-Q · filed 2026-07-30 | ||
| 2025-03-31 | -$79.00K 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $1.64M 10-Q · filed 2025-11-04 | $1.44M derived: sum of 2 quarters · filed 2025-11-04 | $803.00K derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$196.00K 10-Q · filed 2025-11-04 | -$836.00K derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | -$640.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $500.00K 10-K · filed 2026-02-19 | |||
| 2012-03-31 | $16.00K 10-Q · filed 2012-05-03 | |||
| 2011-03-31 | $6.00K 10-Q · filed 2012-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |